CBD Reviews

Zynerba cbd gel

Zygel is the first and only pharmaceutically-produced CBD, a non-euphoric cannabinoid, formulated as a patent-protected permeation-enhanced gel for  Nov 12, 2019 part of an expanding intellectual property portfolio covering the Company's transdermal CBD product candidate, Zygel™ (ZYN002 CBD gel). H. Heussler, J. Cohen, N. Silove, N. Tich, T. Sebree, S. Siegel, and D. Gutterman. Transdermal Cannabidiol (CBD) Gel for the Treatment of Fragile X Syndrome  Zynerba Pharmaceuticals Announces Achievement of Patient Screening New U.S. Patent for Treatment of Fragile X Syndrome with Transdermal Cannabidiol. Sep 5, 2019 Zynerba Pharmaceuticals is on track to report top-line results from tests of Zygel, a CBD gel treatment for children and adolescents with Fragile  Oct 14, 2019 Zynerba's CBD gel to treat Fragile X syndrome ventures where Big Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) is doing trailblazing work 

Zynerba shares surge after Main Line firm wins patent for its CBD

Zynerba Pharmaceuticals Announces Initiation of STAR 2 Open-Label

Rationale: Cannabidiol (CBD) can reduce seizures in patients with epilepsy. the safety and efficacy of ZYN002 (transdermal CBD gel) as adjunctive therapy for Funding: This study was supported by Zynerba Pharmaceuticals, Inc. Figures: 

ZYN002 CBD gel was shown to be safe and well-tolerated across range of doses tested in healthy subjects and adult epilepsy patients with focal seizuresNo impairment in cognitive performance or | December 5, 2016 Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYNE Zynerba Pharmaceuticals Inc Zynerba Pharmaceuticals Announces Positive Top Line Results from ZYN002 CBD Gel Phase 1 Multiple Rising Dose Trial and Initia

Zynerba Pharmaceuticals to Highlight Data for ZYN002 CBD Gel at

Results are in from a Phase 2 clinical trial of a CBD-based gel formulated to treat a congenital condition known as Fragile-X syndrome, a condition which causes mild to severe intellectual disability. The experimental drug known as ZYN002 is being developed by Zynerba Pharmaceuticals. Data collected in the study suggests that one year of treatment with the topically applied drug can provide